Organigram Global Inc Stock Price, News & Analysis

Organigram Global (NASDAQ: OGI) (TSX: OGI), Canada's #1 cannabis company by market share, has released the recording of its OG Investor Session, now available online for shareholders, analysts, and industry stakeholders.

The virtual event features presentations from the company's senior leadership team, including tours of its five state-of-the-art facilities across Canada and a live Q&A session. CEO Beena Goldenberg emphasized the session's importance in communicating the company's growth trajectory and industry opportunities.

The recorded session covers key themes including:

• Strengthening Organigram's position as a global leader in branded cannabis products
• Leveraging science and IP for product innovation and margin expansion
• Updates on cost-efficiency programs and automation
• Progress on international sales and regulatory developments

Organigram Global (NASDAQ: OGI), Canada's leading cannabis company by market share, released new public opinion data showing strong national support for growing Canada's cannabis industry. The survey, conducted by Abacus Data in April 2025, reveals that 57% of Canadians view cannabis as important to today's economy, while 62% believe it could play an even more significant role in the future.

The poll shows that 64% of Canadians support increased federal government assistance for the legal cannabis sector, with support highest among ages 18-29 (73%) and maintaining majority support (57%) even among those 60 and over. Regional support is strongest in Atlantic Canada (65%), followed by the Prairies (64%), Ontario (62%), and British Columbia (61%).

The cannabis industry has contributed over $43 billion to GDP since legalization and supports 80,000 jobs nationwide. In 2024, it added $7.4 billion to Canada's GDP, surpassing traditional industries like breweries ($2.6B), forestry and logging ($3.3B), and wineries and distilleries ($1.2B).

Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) has announced its first-ever virtual investor event, the OG Investor Session, scheduled for April 10, 2025, at 4pm EST. The online event will provide investors with insights into the company's growth strategy and industry trends.

Key presenters include:

• CEO Beena Goldenberg discussing vision and market strategy
• CFO Greg Guyatt covering financial performance
• SVP Borna Zlamalik presenting R&D and innovation
• Director of IR Max Schwartz hosting

The event will feature behind-the-scenes facility tours and a live Q&A session with senior management. Additionally, the company has announced its official name change to Organigram Global Inc., with shares continuing to trade under the symbol 'OGI' on both TSX and NASDAQ. New CUSIP (68617J100) and ISIN (CA68617J1003) numbers have been assigned to common shares.

Organigram (NASDAQ: OGI), Canada's leading cannabis company by market share, has acquired Collective Project (CPL) for C$6.2 million upfront, with potential milestone and earnout payments up to C$24M through 2026.

The acquisition marks Organigram's entry into the U.S. hemp-derived THC beverage market and accelerates its presence in the Canadian cannabis beverage category. Collective Project, launched by Hamilton-based Collective Arts, produces cannabis and hemp-derived infused sparkling juices, teas, and sodas.

The strategic acquisition provides immediate access to the U.S. market, where Collective Project products are already available in multiple states and retailers. The hemp-derived THC beverage market is projected to grow from current $1 billion to $4 billion by 2028. In Canada, CPL currently holds 5.6% of the beverage category with distribution across several provinces.

Organigram Holdings Inc (NASDAQ: OGI) (TSX: OGI) has announced its rebranding to Organigram Global Inc, marking its evolution from a regional medical cannabis company to a global cannabis leader. The company, which has achieved the #1 market share position in Canada, unveiled a new visual identity including a new logo and website.

The expansion strategy includes a strategic investment in German cannabis leader Sanity Group, which holds 7% market share and distributes to over 2,000 pharmacies. The company is pursuing EU-GMP certification to scale exports and expects higher margins from international sales. Organigram currently exports to Australia, Germany, and the United Kingdom, with plans to increase shipments.

The company maintains two US investments: Open Book Extracts for hemp-derived products and Phylos Bioscience for cannabis genetics. Trading under the symbol 'OGI' will continue on both TSX and NASDAQ, with the name change effective March 31, 2025.

Organigram Holdings (TSX: OGI) (NASDAQ: OGI) held its annual general and special meeting on March 24, 2025, where shareholders approved key resolutions. The most significant outcome was the approval of a company name change to Organigram Global Inc., receiving 95.778% affirmative votes. The name change is pending regulatory approvals, including TSX conditional approval.

All ten board nominees listed in the February 12, 2025 management circular were elected. Following the meeting, the company announced updates to its committee compositions, with new arrangements for the Investment Committee and the Governance, Nominating and Sustainability Committee, while the Audit and Compensation Committees remained unchanged.

Shareholders also approved the appointment of PKF O'Connor Davies LLP as the company's auditor with 95.148% of votes in favor, authorizing directors to determine their remuneration.

Organigram Holdings (NASDAQ: OGI) has completed the third and final tranche of its previously announced C$124.56 million strategic equity investment from BAT subsidiary BT DE Investments Inc. The third tranche consisted of 7,562,447 common shares and 5,330,728 Class A preferred shares at C$3.2203 per share, generating gross proceeds of USD$28.96 million.

Following this closing, BAT's subsidiary now owns 30% of Organigram's outstanding common shares and 100% of preferred shares. The investment proceeds will primarily fund the Jupiter Pool, a strategic investment initiative designed to accelerate Organigram's international growth. Currently, approximately C$57.8 million remains available in the Jupiter Pool after previous investments of C$21 million in Sanity Group and C$2.7 million in Open Book Extracts.

Marcus & Millichap's (NYSE:MMI) division IPA has facilitated the sale of Town Deer Valley, a 388-unit multifamily property in Phoenix, Arizona, for $131.1 million ($337,887 per unit). The property was sold by a venture between Rockpoint and The Related Group to Goodman Real Estate.

Completed in 2024, the 18-acre property features premium amenities including a 5,900-square-foot clubhouse, a 3,800-square-foot standalone fitness center, and resort-style swimming facilities. The average unit size is 1,004 square feet, equipped with modern appliances and smart home automation.

The property's strategic location near major employers like USAA, Honeywell, and Wells Fargo, along with proximity to Taiwan Semiconductor's $65 billion chip manufacturing facility, positions it to benefit from the region's economic growth. The area includes 2.7 million square feet of retail space within a three-mile radius.

Organigram Holdings reported Q1 Fiscal 2025 results with 17% growth in net revenue to $42.7 million year-over-year. The company achieved Adjusted EBITDA of $1.4 million, up from $0.1 million in the prior year period. Key highlights include a $2.3 million increase in international sales, completion of Motif acquisition to become Canada's recreational cannabis market leader, and a strong pro-forma cash position of $113 million with negligible debt.

The company maintains leading market positions in Canada, ranking #1 in vapes, pre-rolls, milled flower, hash, and pure CBD gummies. Adjusted gross margin increased to 33% from 31% year-over-year. The integration of Motif is expected to deliver over $10 million in annual run-rate synergies within 24 months. The company's flagship brands SHRED and BOXHOT reached over $385 million in retail sales over the last 12 months.